San Antonio Breast Cancer Symposium | Conference

Sacituzumab Govitecan Shows Sustained Survival Improvement in HR+/HER2– Breast Cancer

December 10th 2022

Sacituzumab govitecan prolonged survival vs treatment of physician’s choice in pretreated patients with hormone receptor–positive, HER2-negative metastatic breast cancer regardless of Trop-2 expression, according to updated findings from the phase 3 TROPiCS-02 trial.

Neoadjuvant Olaparib Combo Fails to Surpass Carboplatin/Paclitaxel in HER2– Early Breast Cancer

December 9th 2022

Long-term clinical data failed to show a benefit of neoadjuvant olaparib (Lynparza) plus paclitaxel vs carboplatin plus paclitaxel in patients with HER2-negative early breast cancer with homologous recombination deficiency.

Neoadjuvant Cemiplimab/REGN3767 Plus Paclitaxel Improves pCR in Early-stage, High-risk HER2– Breast Cancer

December 9th 2022

The addition of cemiplimab and REGN3767 to paclitaxel improved pathologic complete response vs paclitaxel alone in patients with triple-negative and hormone receptor–positive, HER2-negative breast cancer, according to data from the phase 2 I-SPY2 trial.

Dr. Oliveira on the Examination of Camizestrant Vs Fulvestrant in ER+/HER2- Breast Cancer

December 9th 2022

Mafalda Oliveira, MD, PhD, discusses the examination of camizestrant vs fulvestrant in estrogen receptor-positive, HER2-negative advanced breast cancer.

Trastuzumab Deruxtecan With or Without Pertuzumab Demonstrates Early Safety and Efficacy Signals in HER2+ MBC

December 9th 2022

Trastuzumab deruxtecan, both as monotherapy and in combination with pertuzumab, displayed encouraging efficacy with no new safety signals among patients with HER2-positive metastatic breast cancer, according to findings from the dose expansion part of the phase 1b/2 DESTINY-Breast07 trial.

Dr. Jacot on Ribociclib Dose Reduction in HR+/HER2– Advanced Breast Cancer

December 9th 2022

William Jacot, MD, PhD, discusses updated efficacy and safety results from the phase 2 AMALEE trial.

CTC Count-driven Approach to First-line Treatment in Metastatic Breast Cancer Improves Survival

December 9th 2022

Using circulating tumor cell count as a guide to first-line treatment, either with chemotherapy or endocrine therapy, resulted in an improvement in overall survival compared with physician’s choice of treatment without CTC count for patients with metastatic, hormone receptor–positive/HER2-negative breast cancer.

Benefit of Elacestrant Improves With Longer Duration of CDK4/6 Inhibition in Patients With ER+/HER2– Metastatic Breast Cancer

December 8th 2022

Treatment with the oral selective estrogen receptor degrader elacestrant following treatment with CDK4/6 inhibitors improved progression-free survival outcomes vs standard care options in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.

Palbociclib Plus Fulvestrant Fails to Improve PFS in ER+/HER2- Breast Cancer After Progression on a CDK4/6 inhibitor

December 8th 2022

Palbociclib plus fulvestrant did not elicit a progression-free survival benefit vs fulvestrant alone in patients with estrogen receptor–positive/HER2-negative breast cancer who had progressed on prior treatment with a CDK4/6 inhibitor and aromatase inhibitor.

ARV-471 Monotherapy Demonstrates Clinical Benefit in ER+/HER2- Advanced Breast Cancer

December 8th 2022

ARV-471 monotherapy elicited a significant clinical benefit rate in patients with estrogen receptor–positive/HER2-negative locally advanced or metastatic breast cancer who had undergone prior hormonal therapy and chemotherapy, including those with ESR1 mutations.

Camizestrant Provides Survival Benefit Vs Fulvestrant in ER+/HER2- Advanced Breast Cancer

December 8th 2022

Two separate doses of single-agent camizestrant monotherapy improved progression-free survival vs standard-of-care fulvestrant in patients with estrogen receptor-positive, HER2-negative advanced breast cancer.

Dr. Bardia on Elacestrant in ER+/HER2– Metastatic Breast Cancer

December 8th 2022

Aditya Bardia, MD, MPH, discusses the use of elacestrant in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer.

Capivasertib Plus Fulvestrant Elicits PFS Benefit in HR+/HER2- Advanced Breast Cancer

December 8th 2022

The combination of capivasertib plus fulvestrant significantly improved progression-free survival vs fulvestrant alone in patients with hormone receptor–positive/HER2-negative advanced breast cancer, including those with AKT pathway–altered tumors.

Real-world Data Confirm Safety Profile for Tucatinib Plus Trastuzumab/Capecitabine in HER2+ Breast Cancer

December 8th 2022

The safety profile for the combination of tucatinib, trastuzumab, and capecitabine from the phase 3 HER2CLIMB trial was confirmed with real-world data for patients with HER2-positive metastatic breast cancer.

Dr. Hurvitz on Trastuzumab Deruxtecan in Unresectable/Metastatic HER2+ Breast Cancer

December 7th 2022

Sara A. Hurvitz, MD, discusses updated survival data with fam-trastuzumab deruxtecan-nxki in HER2-positive, unresectable/metastatic breast cancer.

Eribulin Demonstrates Comparable Efficacy to Traditional Chemotherapy Options in HER2-low and HER2-0 Metastatic Breast Cancer

December 7th 2022

Eribulin mesylate demonstrated a trend toward improved outcomes vs other chemotherapy options of physician’s choice in patients with HER2-low or HER2-0 metastatic breast cancer who were previously treated with at least 1 chemotherapy.

Yoga, Exercise Associated With Better Survival in Nonmetastatic Breast Cancer

December 7th 2022

Patients with non-metastatic breast cancer undergoing treatment who added yoga to conventional exercises experienced improvements in disease-free survival, overall survival, and long-term quality of life vs those who did conventional exercises alone.

Trastuzumab Deruxtecan Continues to Best T-DM1 Survival Rates With Longer Follow-Up in HER2+ Metastatic Breast Cancer

December 7th 2022

Patients with HER2-positive metastatic breast cancer experienced a significant survival benefit when treated with fam-trastuzumab deruxtecan compared with trastuzumab emtansine.

Trastuzumab Deruxtecan, With or Without Endocrine Therapy, Shows Promising Responses in Operable HR+, HER2-Low Breast Cancer

December 7th 2022

Neoadjuvant treatment with trastuzumab deruxtecan showed promising responses in patients with early-stage breast cancer.

Trastuzumab Deruxtecan Generates PFS, OS Benefit Vs Capecitabine-based Regimens in Pretreated HER2+ Breast Cancer

December 7th 2022

Trastuzumab deruxtecan demonstrated a 64% reduction in the risk of disease progression or death compared with physician's choice of treatment in patients with advanced HER2-positive unresectable and/or metastatic breast cancer who previously received ado-trastuzumab emtansine.